132 results about "Risk of death" patented technology

A system comprising an implantable medical device (IMD). The IMD comprises a ventricular heart signal sensing circuit to provide a ventricular heart signal, at least one sensor operable to provide an electrical signal representative of patient activity, a sensor interface circuit coupled to the at least one sensor to provide an activity signal, and a controller circuit coupled to the heart signal sensing circuit and the sensor interface circuit. The controller circuit is operable to determine whether ventricular ectopy occurs during recovery from exercise using the heart signal, and to set at least one warning indicator if ventricular ectopy occurs during the recovery from exercise.

A method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy is provided. The method includes receiving cardiac data and determining a cardiac index based upon the cardiac data. The method includes determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. Also presented is a second method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy comprising receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively. The second method includes determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A computer readable program storage device is also provided. Also provided is a method for receiving body data, determining a cardiac, an arousal, a responsiveness, or a kinetic index, determining an increased or increasing risk of death over a first time window relating to a patient with epilepsy and issuing a warning and logging relevant information.

The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.

A statistical processing system to predict end of life status in current patients of a given population. The processing system includes a server configured with programming instructions implementing a plurality of statistical models to predict a health status or outcome for the highest risk of death based on proprietary factors and the patient being administered no further therapeutic treatment.

The invention provides an early death risk assessment model establishing method and device based on ensemble learning. The method and device are used for assessing the death risk of an old multi-organfailure patient during hospitalization based on diagnosis and treatment data of the first day when the old multi-organ failure patient enters an intensive care unit. The method comprises the steps ofdata set construction, data processing and model construction and evaluation. The method comprises the following steps: acquiring three pieces of demographic information, five pieces of vital sign information, five laboratory examination indexes and two clinical indexes of a patient on the first day during living in an intensive care unit; inputting the data into a risk assessment device, and carrying out internal data preprocessing, feature calculation and model operation. Finally, the risk of adverse outcomes in the hospital of the patient can be predicted early, and doctors are helped to treat the patient as soon as possible.

A method includes receiving cardiac data and determining a cardiac index based upon the cardiac data; determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A second method comprises receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively; determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A non-transitory computer readable program storage device encoded with instructions that, when executed by a computer, perform a method is also provided.

The present application provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF, and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.

The invention comprises A comprises a system and method for hedging or mitigating mortality exposure risk in a portfolio of mortality-dependent instruments. A mortality risk or longevity risk of the portfolio is calculated or otherwise determined. Then the sensitivity of the portfolio to mortality risk or longevity risk is calculated or otherwise determined, in other words, how much is cost or value of the portfolio affected by a change in mortality rate. To account for that mortality exposure, a selection is made of building block mortality derivatives that include age-based mortality derivatives. The selected plurality of selected plurality of building block mortality derivatives are used to create a hedge against the mortality risk or longevity risk of the portfolio.

The present invention discloses a method of applying novel bioinformatics and computational methodologies to data generated by high-resolution genome-wide comparative genomic hybridization and gene expression profiling on CD138-sorted plasma cells from a cohort of 92 newly diagnosed multiple myeloma patients treated with high dose chemotherapy and stem cell rescue. The results revealed that gains the q arm and loss of the p arm of chromosome 1 were highly correlated with altered expression of resident genes in this chromosome, with these changes strongly correlated with 1) risk of death from disease progression, 2) a gene expression based proliferation index, and 3) a recently described gene expression-based high-risk index. Importantly, we also found a strong correlation between copy number gains of 8q24, and increased expression of Argonate 2 (AGO2) a gene coding for a master regulator of microRNA expression and maturation, also being significantly correlated with outcome. Our novel findings significantly improve our understanding of the genomic structure of multiple myeloma and its relationship to clinical outcome.

The invention especially relates to molecular markers, internal reference genes and application thereof, a detection kit and a method for constructing a detection model, belonging to the field of biotechnology. With follow-up information used for comparison, the kit provided by the invention has accuracy of 70% in predication of the risk of recurrence or death of first-visit patients with ER-positive and PR-positive breast cancers in 3-10 years after operations, wherein the prediction accuracies of a low-risk group and a high-risk group are 81.1% and 54.4%, respectively while the prediction accuracies of corresponding FFPE pathological examination results are 71.9 to 56.8%, respectively. The risk prediction model matching with the kit only needs the Ct values of the molecular markers, theage of a patient, the stage of pT and the number of LN and does not depend on other clinical pathological information, so the risk prediction model has better performance in evaluation of prognosis ofbreast cancers than simple pathological prediction results, can reduce malpractice caused by errors in pathological prediction and further improves a technical method for evaluation of prognosis of breast cancers.

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

The invention discloses a cyclic RNA molecular marker for predicting prognosis and death risk of colorectal cancer and application of the cyclic RNA molecular marker. The cyclic RNA molecular marker is prepared from circRNA13452, hsa_circ_0008039, hsa_circ_0079480 and hsa_circ_0087391; the cDNA sequences of the cyclic RNA molecular marker are as shown in SEQ ID NO:1 to 4 sequentially. By detectingthe expression levels of the four cyclic RNA molecules in tissues of medium-term colorectal cancer patients and using corresponding predictive models, the aim of predicting the prognosis and death risk of the patients is realized; the accuracy of predicting the prognosis and death risk by using tissue specimens of the colorectal cancer patients is improved; the cyclic RNA molecular marker has great significance for further diagnosis and treatment scheme and prolonging of lifetime of the patients.

The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject.

The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.

The invention discloses a use of endogenous metabolites as markers for predicting the prognosis risk of coronary heart disease or in preparation of a kit for predicting the prognosis risk of coronaryheart disease. The metabolite marker can effectively predict the risk of death and major adverse cardiovascular events (MACE) in patients with coronary heart disease and the risk of cardiac insufficiency, and has the characteristics of specificity, sensitivity, high efficiency and non-invasiveness. After the metabolite marker is used for predicting the prognosis survival rate of patients with coronary heart disease, the AUC is 65% or more. Through combination, the AUC is close to 100% compared with AUC based on the single marker and the prediction effect is good. The method for detecting through the marker has high sensitivity, is convenient and quick and produces accurate and reliable results. The predictive model constructed by the marker can be used for predicting the prognosis risk ofcoronary heart disease, has good predictive effects and high sensitivity, is convenient, rapid and non-invasive and has an important clinical application value.

A safety evacuation system for drivers and passengers of ground and water vehicles is proposed. The system is comprised of a sensor system, computer implemented model of risk assessments from collisions with surrounding objects, control system, safety escape channels, and ejection seats. The sensor system measures directions, speeds and distances of a vehicle to all objects, which may collide with the vehicle and pose risk of deaths or injures to humans in the vehicle. The computer-implemented model assesses the risk of deaths and injuries for humans, based on the measurements of the sensor system. The control system opens the escape channel and activates ejection seats based on the risk assessments from the computer-implemented model.

The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.

The invention provides a pulmonary embolism clinical risk and prognosis scoring method and a system, and the method comprises the steps: carrying out the screening and feature extraction of medical data, and obtaining influence factors corresponding to death; performing single-factor logistic regression analysis on the influence factors, determining variables of a prognosis model, and establishing a logistic regression model; obtaining a result OR value through statistical analysis; assigning each risk factor based on the OR value, and establishing a risk prediction scoring system of pulmonary embolism to predict the death risk of the pulmonary embolism patient within 30 days; constructing an ROC curve, and comparing the areas under the curve of the three scoring systems by using clinical data of the verification group, the modeling group and the modeling group + the verification group; and predicting a result according to the optimal truncation value. The risk and prognosis scoring method can evaluate the death risk of the pulmonary embolism patient within 30 days, and high-risk and low-risk patients can be identified for doctors to refer to and formulate a diagnosis scheme.

The invention provides a group of DNA methylation markers for evaluating survival prognosis risk of coronary heart disease. The marker comprises methylation sites corresponding to the following genes:chr3: 101901234, SEMA3B, CORO2B, SLC39A8, chr7: 27235733, chr10: 3086002, chr2: 164594200, RNASEH1, chr10: 13489731, ABCA3, ZNF444, UBE2E2, DAZAP1, NAT10, DDAH1 and FKBP5. Prognosis and death risks of coronary heart disease patients can be predicted by monitoring changes of methylation levels of the 16 sites. The invention also constructs a model for evaluating the survival prognosis risk of thecoronary heart disease based on the 16 methylation sites, and the accuracy of blood diagnosis and prognosis prediction of patients with the coronary heart disease can be improved through the model. According to the method, the Lasso Cox regression model is used for screening important variables, so that the model dimension is greatly reduced, the detection cost is favorably reduced, and the popularization in clinical application is facilitated.

Provided are methods for predicting survival outcome of an individual suffering from congestive heart failure. In accordance with the method, a patient's survival outcome is determined by taking into consideration the levels of two markers in combination, the combination being more predictive of survival than either marker alone. The markers include endothelin, atrial natriuretic peptide and brain natriuretic peptide, their precursors and fragments thereof. Individuals with congestive heart failure identified as having increased risk of mortality using the methods of the invention are appropriately targeted for more aggressive therapy.

The present invention discloses a patient heart failure death risk prediction system based on a characteristic rearrangement one-dimensional convolution neural network. The method comprises the following steps: acquiring an original data set of patients with heart failure from an electronic medical record system of a hospital; performing a characteristic engineering pretreatment on the acquired data set, wherein the characteristic engineering pretreatment comprises performing one-hot encoding mapping on the acquired original data set to obtain a disease-related information characteristic set and forming a corresponding heart failure death data set of the patients together with heart failure death labels of the patients in the original data set; performing characteristic rearrangement on the data set based on chi-square correlation analysis, arranging characteristics in a descending order from high to low according to correlation with heart failure death of the patients, and screening arearranged characteristic subset; and using the convolution neural network to conduct heart failure death prediction training of the patients. The patient heart failure death risk prediction system is beneficial to assisting diagnosis and treatment of heart failure diseases and improving clinical nursing conditions of the patients.

The invention discloses a sow delivery time prediction system based on late pregnancy posture conversion characteristics, which is characterized by comprising an image acquisition module, a network transmission module, a video storage unit, a local server, a central computing module and a mobile terminal receiving module, the image acquisition module acquires a sow video in a post-pregnancy deadline column environment, and the acquired data is stored in the video storage unit; and the screenshot image frames of the local server are uploaded to the central computing module through the network transmission module. According to the invention, end-to-end automatic operation and control are realized from the image acquisition module to the final mobile terminal receiving module, the sow management efficiency can be greatly improved, and the death risk of piglets is reduced.